Protagonist Therapeutics PTGX
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–
Analyst view
ConsensusBuy
Analysts13
Average target$180.00+48.3% vs. price
- Buy 100%
Low $151.00Now $121.40Avg $180.00High $221.00
Recent rating changes
The last 20 actions on file set price targets from $151.00 to $221.00, averaging $181.26.
| Date | Firm | Rating | Target |
|---|---|---|---|
| 10 Nov 2026 | UBS | BUY | $184.00 |
| 9 Nov 2026 | Wedbush | BUY | $173.00 |
| 9 Nov 2026 | BMO Capital | BUY | $190.00 |
| 9 Nov 2026 | J.P. Morgan | BUY | $151.00 |
| 6 Nov 2026 | H.C. Wainwright | BUY | $221.00 |
| 6 Nov 2026 | Barclays | BUY | $180.00 |
| 5 Nov 2026 | BMO Capital | BUY | $190.00 |
| 3 Nov 2026 | UBS | BUY | $184.00 |
| 2 Nov 2026 | UBS | BUY | $184.00 |
| 21 Oct 2026 | TD Cowen | BUY | $160.00 |
| 15 Oct 2026 | Citi | BUY | $182.00 |
| 13 Oct 2026 | Barclays | BUY | $180.00 |
| 12 Oct 2026 | UBS | BUY | $184.00 |
| 12 Oct 2026 | Leerink Partners | BUY | $190.00 |
| 11 Oct 2026 | UBS | BUY | $184.00 |
| 9 Sep 2026 | Citi | BUY | $182.00 |
| 1 Sep 2026 | Truist Financial | BUY | – |
| 1 Sep 2026 | Citi | BUY | $182.00 |
| 1 Sep 2026 | H.C. Wainwright | BUY | $170.00 |
| 31 Aug 2026 | Clear Street | BUY | $173.00 |
No comments yet — be the first to weigh in on PTGX.
Sign in to join the discussion.